Angeletti C A, Mussi A, Janni A, Lucchi M, Ribechini A, Chella A, Fontanini G
Department of Thoracic Surgery, University of Pisa, Italy.
Eur J Cardiothorac Surg. 1995;9(11):607-11. doi: 10.1016/s1010-7940(05)80104-6.
During a 14-year period (1980-1993) second primary lung cancer or relapse was treated in 44 consecutive patients. Thirty-seven patients had synchronous (n = 18) or metachronous (n = 19) second primary lung cancer. Ten synchronous tumors were ipsilateral and treated contemporarily with five pneumonectomies, three lobectomies and two double wedge resections. The bilateral synchronous lesions (8 patients) were treated by staged bilateral thoracotomy (mean interval; 2 months). The first resection consisted of a lobectomy in six patients and wedge resection in two. The second one was a wedge resection in six patients and a lobectomy in two. In the metachronous presentation 15 patients (79%) were asymptomatic and detected by follow-up chest X-ray. In this group the first operation was a lobectomy in 12 patients, a wedge resection or segmentectomy in 6 and a pneumonectomy in 1. The second one was a wedge resection in nine patients, a lobectomy in six and completion pneumonectomy in four. Seven patients, all of them asymptomatic, had local recurrence from their primary lung cancer. The first lung resection was a lobectomy in five patients and a wedge resection in two. The second one was completion pneumonectomy in five patients and completion lobectomy in two. We had no operative death. The actuarial over-all 5-year survival rate after the second pulmonary resection for second primary lung cancer was 38.3% with a median survival time of 13.5 months. The synchronous presentation had a better survival than the metachronous one (46.2% and 25.9%), respectively). The actuarial overall 5-year survival rate for patients with relapse was 38.1% with a median survival time of 37 months. We may conclude that an aggressive surgical approach is safe, effective and warranted in patients with either a second primary lung cancer or relapse from their primary lung cancer. Moreover, for early detection of the second lesions, follow-up at a maximum of 6-monthly intervals should be continued for more than 5 years after the first resection.
在14年期间(1980 - 1993年),对44例连续性患者的第二原发性肺癌或复发进行了治疗。37例患者患有同时性(n = 18)或异时性(n = 19)第二原发性肺癌。10例同时性肿瘤位于同侧,同期接受了5例全肺切除术、3例肺叶切除术和2例双楔形切除术。双侧同时性病变(8例患者)采用分期双侧开胸手术治疗(平均间隔时间为2个月)。首次切除术包括6例患者的肺叶切除术和2例患者的楔形切除术。第二次手术是6例患者的楔形切除术和2例患者的肺叶切除术。在异时性病例中,15例患者(79%)无症状,通过胸部X线随访发现。在该组中,首次手术12例患者为肺叶切除术,6例为楔形切除术或肺段切除术,1例为全肺切除术。第二次手术9例患者为楔形切除术,6例为肺叶切除术,4例为全肺切除术。7例患者均无症状,其原发性肺癌出现局部复发。首次肺切除术5例患者为肺叶切除术,2例为楔形切除术。第二次手术5例患者为全肺切除术,2例为肺叶切除术。我们没有手术死亡病例。第二原发性肺癌第二次肺切除术后的实际5年总生存率为38.3%,中位生存时间为13.5个月。同时性病例的生存率高于异时性病例(分别为46.2%和25.9%)。复发患者的实际5年总生存率为38.1%,中位生存时间为37个月。我们可以得出结论,对于患有第二原发性肺癌或原发性肺癌复发的患者,积极的手术方法是安全、有效的,并且是必要的。此外,为了早期发现第二个病变,首次切除术后应继续每6个月进行一次随访,持续5年以上。